PPD Plans Major Suzhou Lab to Offer China Drug Development Services
publication date: Oct 15, 2020
PPD, a global CRO, announced plans to build a new laboratory in Suzhou to support China drug development. The 67,000-square-foot facility, which will offer bioanalytical, biomarker and vaccine services, will hire an additional 350 staff members. Planned for completion in 2021, the facility will be located in the Suzhou New District, Jiangsu Province. PPD already operates a Shanghai central lab that offers safety and efficacy testing, custom specimen collection kits and biorepository services for clinical trials. More details....
Stock Symbol: (NSDQ: PPD)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.